Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARA-002 in High-grade Non-muscle Invasive Bladder Cancer
2023-505062-28-00Phase 2Withdrawn
- Sponsor
- Protara Therapeutics
- Start
- Sep 2023
- Modality
- Cell Therapies
- Countries
- 4
01
Overview
Phase 2, open-label trial of TARA-002 in bladder cancer (2 cohorts), sponsored by Protara Therapeutics. Primary endpoints: Cohort A: incidence of high-grade complete response (CR) at any time, Cohort A: incidence of high-grade complete response (CR) at any time by subgroup and 1 more. Planned start Sep 2023; status: withdrawn.
02
Drugs
TARA-002
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2023-505062-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505062-28-00.